NVCR
Novocure·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Ample Liquidity
High Gross Profit Margin
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NVCR
Novocure Limited
A global oncology company that develops novel therapy for the treatment of solid tumor cancers including glioblastoma brain cancer
Healthcare Equipment and Supplies
02/11/2000
10/02/2015
NASDAQ Stock Exchange
1,488
12-31
Common stock
No. 4 The Forum, Grenville Street, St. Helier, Jersey JE2 4UF
--
Novocure Limited is a public limited liability company incorporated under the laws of the Channel Islands of Jersey on February 11, 2000. The company is a commercial anti-tumor company that has developed a new proprietary therapy known as Oncology Therapeutics, or TTFields, to fight solid tumor cancers.
Earnings Call
Q2/2025
Estimate EPS-0.39
Actual EPS-0.36
Estimate Revenue154.20M
Actual Revenue158.80M
Novocure's Q2 2025 Earnings Call: Unpacking Contradictions in Optune Lua Growth and Revenue Recognition
Jul 25,2025 08:58
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
NVCR has released its 2025 Q3 earnings. EPS was reported at -0.33, versus the expected -0.42, beating expectations. The chart below visualizes how NVCR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NVCR has released its 2025 Q3 earnings report, with revenue of 167.20M, reflecting a YoY change of 7.81%, and net profit of -37.27M, showing a YoY change of -21.92%. The Sankey diagram below clearly presents NVCR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
